checkAd

     105  0 Kommentare Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting

    All dollar amounts reflected in Canadian dollars unless otherwise stated

    VANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press release dated May 23, 2024, that it has received subscriptions totalling $1.7 million for its previously announced $1.5 million private placement. The terms of the private placement otherwise remain unchanged. To accommodate additional interest, the Company will upsize the financing to $2.0 Million, subject to TSX-V approval. The Company anticipates a first closing of the private placement on or about June 25, 2024.

    “Rakovina Therapeutics has benefited greatly from the support of our long-term shareholders. With this financing we are pleased to welcome a new group of investors to the Company,” said Rakovina Therapeutics’ Executive Chairman, Jeffrey Bacha.

    “These funds will be used to further accelerate research activities related to our recently announced AI drug-discovery partnership and expanded collaboration with the University of British Columbia and Pharma Inventor Inc. We remain steadfast in our mission to develop new treatments to improve the lives of those affected by cancer,” he added.

    AGM Elections
    The Company is also pleased to announce the results of voting at its 2024 annual general meeting of shareholders held on June 20, 2024, in Vancouver, British Columbia (the “Meeting”).

    All four members of the Company’s board of directors named as nominees in its management information circular dated May 20, 2024 (the “Circular”) were re-elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia and Michael Liggett.

    In addition, at the Meeting, the shareholders of the Company: (i) approved the re-appointment of Davidson & Company LLP as the Company’s auditor until the next annual general meeting of shareholders; and (ii) re-approved the Company’s existing omnibus equity incentive plan as set out in the Circular.

    About Rakovina Therapeutics Inc.
    Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

    Seite 1 von 2



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) - Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new …